Krabeva 100 mg Injection

Product Description

Krabeva 100 mg Injection is a targeted therapy used in the treatment of various types of cancer, including colorectal cancer, non-small cell lung cancer, glioblastoma, kidney cancer, and ovarian cancer. This medication contains Bevacizumab, a monoclonal antibody that effectively inhibits vascular endothelial growth factor (VEGF), a protein that promotes the growth of blood vessels that tumors need to thrive. By blocking VEGF, Krabeva helps to starve tumors of their blood supply, ultimately slowing their growth and spread. Patients receiving this injection may experience side effects such as high blood pressure or bleeding, and regular monitoring by healthcare professionals is essential to ensure safety and efficacy during treatment. It is important to inform your doctor about any existing health conditions or medications you are taking, as these can influence the effectiveness and safety of Krabeva. Administered alongside other cancer therapies, Krabeva 100 mg Injection represents a vital component of modern oncological treatment strategies. Always consult your healthcare provider for personalized advice and to discuss the potential benefits and risks associated with this innovative cancer therapy.